Human cytomegalovirus protease: Why is the dimer required for catalytic activity?

Journal of Chemical Theory and Computation

Volumn 3, Issue 1, 2007, Pages 278-288

  De Oliveira, César Augusto Fernandas ^a,c   Guimarães, Cristiano Ruch Werneck ^b,d   Barreiro, Gabriela ^b,e   De Alencastro, Ricardo Bicca ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AMGEN INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35048892446     PISSN: 15499618     EISSN: None     Source Type: Journal    
DOI: 10.1021/ct600175x     Document Type: Article

References (63)

1. Corey, L.; Spear, P. G. N. Infections with Herpes-Simplex Viruses 1. N. Engl. J. Med. 1986, 314, 686-691.
2. Roizman, B.; Desrosiers, R. C.; Fleckenstein, B.; Lopez, C.; Minson, A. C.; Studdert, M. J. The Family Herpesviridae: An Update. Arch. Virol. 1992, 123, 425-449.
3. Holwerda, B. C. Herpesvirus Proteases: Targets for Novel Antiviral Drugs. Antiviral Res. 1997, 35, 1-21.
4. de Jong, M. D.; Galasso, G. J.; Gazzard, B.; Griffiths, P. D.; Jabs, D. A.; Kern, E. R.; Spector, S. A. Summary of the II International Symposium on Cytomegalovirus. Antiviral Res. 1998, 39, 141-162.
5. Nichols, W. G; Boeckh, M. Recent Advances in the Therapy and Prevention of CMV Infections. J. Clin. Virol. 2000,16, 25-40.
6. Bruggeman, C. A.; Marjorie, H. J.; Nelissen-Vrancken, G. Cytomegalovirus and Atherogenesis. Antiviral Res. 1999, 43, 133-144.
7. Jong, M. D.; Boucher, C. A. B.; Danner, S. A.; Gazzard, B.; Griffiths, P. D.; Katlama, C.; Lange, J. M. A.; Richman, D. D.; Vella, S. Summary of the International Consensus Symposium on Management of HIV, CMV and Hepatitis Virus Infections. Antiviral Res. 1998, 37, 1-16.
8. Gilbert, C.; Boivin, G. Human Cytomegalovirus Resistance to Antiviral Drugs. Antimicrob. Agents Chemother. 2005, 49, 873-883.
9. De Clercq, E. Antiviral Drugs in Current Clinical Use. J. Clin. Virol. 2004, 30, 115-133.
10. De Clercq, E. New Inhibitors of Human Cytomegalovirus (HCMV) on the Horizon. J. Antimicrob. Chemother. 2003, 51, 1079-1083.
11. De Clercq, E. Strategies in the Design of Antiviral Drugs. Nat. Rev. Drug Discovery 2002, 1, 13-25.
12. De Clercq, E. Antiviral Drugs: Current State of the Art. J. Clin. Virol. 2001, 22, 73-89.
13. Eizuru, Y. Development of New Antivirals for Herpesviruses. Antiviral Chem. Chemother. 2003, 14, 299-308.
14. Emery, V. C. Progress in Understanding Cytomegalovirus Drug Resistance. J. Clin. Virol. 2001, 21, 223-228.
15. Gibson, W.; Welch, A. R.; Hall, M. R. T. Assembling, a Herpes Virus Serine Maturational Proteinase and New Molecular Target for Antivirals. Perspect. Drug Discovery Des. 1994, 2, 413-426.
16. Matusick-Kumar, L.; McCann, P. J.; Robertson, B. J.; Newcomb, W. W.; Brown, J. C.; Gao, M. Release of the Catalytic Domain N(o) from the Herpes Simplex Virus Type 1 Protease Is Required for Viral Growth. J. Virol. 1995, 69, 7113-7121.
17. Gao, M.; Matusick-Kumar, L.; Hurlburt, W.; DiTusa, S. F.; Newcomb, W. W.; Brown, J. C.; McCann, P. J.; Deckman, I.; Colonno, R. J. The Protease of Herpes-Simplex Virus Type-1 Is Essential for Functional Capsid Formation and Viral Growth. J. Virol. 1994, 68, 3702-3712.
18. Gopalsamy, A.; Lim, K.; Ellingboe, J. W.; Mitsner, B.; Nikitenko, A.; Upeslacis, J.; Mansour, T. S.; Olson, M. W.; Bebernitz, G. A.; Grinberg, D.; Feld, B.; Moy, F. J.; O'Connell, J. Design and Syntheses of 1,6-Naphthalene Derivatives as Selective HCMV Protease Inhibitors. J. Med. Chem. 2004, 47, 1893-1899.
19. Borthwick, A. D.; Angier, S. J.; Crame, A. J.; Exall, A. M.; Haley, T. M.; Hart, G. J.; Mason, A. M.; Fennel, A. M. K; Weingarten, G. G. Design and Synthesis of Pyrrolidine-5,5-trans-lactams (5-Oxo-hexahydro-pyrrolo[3,2-b] pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 1. The Alpha-methyl-trans-lactam Template. J. Med. Chem. 2000, 43, 4452-4464.
20. Dhanak, D.; Burton, G.; Christmann, L. T.; Darcy, M. G.; Elrod, K. C.; Kaura, A.; Keenan, R. M.; Link, J. O.; Peishoff, C. E.; Shah, D. H. Metal Mediated Protease Inhibition: Design and Synthesis of Inhibitors of the Human Cytomegalovirus (hCMV) Protease. Bioorg. Med. Chem. Lett. 2000, 10, 2279-2282.
21. Dhanak, D.; Keenan, R. M.; Burton, G.; Kaura, A.; Darcy, M. G.; Shah, D. H.; Ridgers, L. H.; Breen, A; Lavery, P.; Tew, D. G.; West, A. Benzothiopyran-4-one Based Reversible Inhibitors of the Human Cytomegalovirus (HCMV) Protease. Bioorg. Med. Chem. Lett. 1998, 8, 3677-3682.
22. Déziel, R.; Malefant, E. Inhibition of Human Cytomegalovirus Protease N-o with Monocyclic Beta-Lactams. Bioorg. Med. Chem. Lett. 1998, 8, 1437-1442.
23. Yoakim, C.; Ogilvie, W. W.; Cameron, D. R.; Chabot, C.; Guse, L; Haché, B.; Naud, J.; O'Meara, J. A.; Plante, R.; Déziel, R. Beta-Lactam Derivatives as Inhibitors of Human Cytomegalovirus Protease. J. Med. Chem. 1998, 41, 2882-2891.
24. Pinto, I. L.; West, A.; Debouck, C. M.; DiLella, A. G.; Gorniak, J. G.; O'Donnel, K. C.; O'Shannessy, D. J.; Patel, A.; Jarvest, R. L. Novel, Selective Mechanism-Based Inhibitors of the Herpes Proteases. Bioorg. Med. Chem. Lett. 1996, 6, 2467-2472.
25. Patick, A. K.; Potts, K. E. Protease Inhibitors as Antiviral Agents. Clin. Microbiol. Rev. 1998, 11, 614-627.
26. Flynn, D. L.; Abood, N. A.; Holwerda, B. C. Recent Advances in Antiviral Research: Identification of Inhibitors of the Herpesvirus Proteases. Curr. Opin. Chem. Biol. 1997, 1, 190-196.
27. Baum, E. Z.; Bebernitz, G. A.; Hulmes, J. D.; Muzithras, V. P.; Jones, T. R.; Gluzman, Y. Expression and Analysis of the Human Cytomegalovirus-UL80- Encoded Protease Identification of Autoproteolytic Sites. J. Virol. 1993, 67, 497-506.
28. Gibson, W. Action at the Assemblin Dimer Interface. Nat. Struct. Biol 2001, 8, 739-741.
29. LaFemina, R. L.; Bakshi, K.; Long, W. J.; Pramanik, B.; Veloski, C. A.; Wolanski, B. S.; Marcy, A. L; Hazuda, D. J. Characterization of a Soluble Stable Human Cytomegalovirus Protease and Inhibition by M-Site Peptide Mimics. J. Virol. 1996, 70, 4819-4824.
30. Holwerda, B. C.; Wittwer, A. J.; Duffin, K. L.; Smith, C.; Toth, M. V.; Carr, L. S.; Wiegand, R. C.; Bryant, M. L. Activity of 2-Chain Recombinant Human Cytomegalovirus Protease. J. Biol. Chem. 1994, 269, 25911-25915.
31. O'Boyle, D. R.; Wager-Smith, K.; Stevens, J. T.; Weinheimer, S. P. The Effect of Internal Autocleavage on Kinetic-Properties of the Human Cytomegalovirus Protease Catalytic Domain. J. Biol. Chem. 1995, 270, 4753-4758.
32. Tong, L. Viral Proteases. Chem. Rev. 2002, 102, 4609-4626.
33. Welch, A. R.; McNally, L. M.; Hall, M. R. T.; Gibson, W. Herpesvirus Proteinase - Site-Directed Mutagenesis Used to Study Maturational, Release, and Inactivation Cleavage Sites of Precursor and to Identify a Possible Catalytic Site Serine and Histidine. J. Virol. 1993, 67, 7360-7372.
34. Reiling, K. K.; Pray, T. R.; Craik, C. S.; Stroud, R. M. Functional Consequences of the Kaposi's Sarcoma-Associated Herpesvirus Protease Structure: Regulation of Activity and Dimerization by Conserved Structural Elements. Biochemistry 2000, 39, 12796-12803.
35. Hoog, S. S.; Smith, W. W.; Qiu, X. Y.; Janson, C. A.; Hellmig, B.; McQueney, M. S.; ODonnell, K.; OShannessy, D.; DiLella, A. G.; Debouck, C.; Abdel-Meguid, S. S. Active Site Cavity of Herpesvirus Proteases Revealed by the Crystal Structure of Herpes Simplex Virus Protease/Inhibitor Complex. Biochemistry 1997, 36, 14023-14029.
36. Qiu, X.; Janson, C. A.; Culp, J. S.; Richardson, S. B.; Debouck, C.; Smith, W. W.; Abdel-Meguid, S. S. Crystal Structure of Varicella-Zoster Virus Protease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 2874-2879.
37. Chen, P.; Tsuge, H.; Almassy, R. J.; Gribskov, C. L.; Katoh, S.; Vanderpool, D. L.; Margosiak, S. A.; Pinko, C.; Matthews, D. A.; Kan, C. Structure of the Human Cytomegalovirus Protease Catalytic Domain Reveals a Novel Serine Protease Fold and Catalytic Triad. Cell 1996, 86, 835-843.
38. Qiu, X.; Culp, J. S.; DiLella, A. G.; Hellmig, B.; Hoog, S. S.; Janson, C. A.; Smith, W. W.; Abdel-Meguid, S. S. Unique Fold and Active Site in Cytomegalovirus Protease. Nature 1996, 383, 275-279.
39. Shieh, H. S.; Kurumbail, R. G.; Stevens, A. M.; Stegeman, R. A.; Sturman, E. J.; Pak, J. Y.; Wittwer, A. J.; Palmier, M. O.; Wiegand, R. C.; Holwerda, B. C.; Stallings, W. C. Three Dimensional Structure of Human Cytomegalovirus Protease. Nature 1996, 383, 279-282.
40. Tong, L.; Qian, C.; Massariol, M-J.; Bonneau, P.; Cordingley, M.; Lagacé, L. A New Serine-Protease Fold Revealed by the Crystal Structure of Human Cytomegalovirus Protease. Nature 1996, 383, 272-275.
41. Khayat, R.; Batra, R.; Massariol, M.-J.; Lagacé, L.; Tong, L. Investigating the Role of Histidine 157 in the Catalytic Activity of Human Cytomegalovirus Protease. Biochemistry 2001, 40, 6344-6351.
42. Hedstrom, L. Serine Protease Mechanism and Specificity. Chem. Rev. 2002, 102, 4501-4523.
43. Dereweda, Z. S.; Dereweda, U.; Kobos, P. M. (His)C-Epsilon-H⋯O=C Hydrogen-Bond in the Active-Sites of Serine Hydrolases. J. Mol. Biol. 1994, 241, 83-93.
44. Carter, P.; Wells, J. A. (His)C-Epsilon-H⋯-O=C Hydrogen-Bond in the Active-Sites of Serine Hydrolases. Nature 1988, 332, 564-568.
45. Neurath, H. Evolution of Proteolytic-Enzymes. Science 1984, 224, 350-357.
46. Kraut, J. Serine Proteases - Structure and Mechanism of Catalysis. Annu. Rev. Biochem. 1977, 46, 331-358.
47. LaPlante, S. R.; Bonneau, P. R.; Aubry, N.; Cameron, D. R.; Deziel, R.; Grand-Maitre, E.; Plouffe, C.; Tong, L.; Kawai, S. H. Characterization of the Human Cytomegalovirus Protease as an Induced-Fit Serine Protease and the Implications to the Design of Mechanism-Based Inhibitors. J. Am. Chem. Soc. 1999, 121, 2974-2986.
48. Tong, L.; Qian, C.; Massariol, M.-J.; Déziel, R.; Yoakim, C.; Lagacé, L. Conserved Mode of Peptidomimetic Inhibition and Substrate Recognition of Human Cytomegalovirus Protease. Nat. Struct. Biol. 1998, 5, 819-826.
49. Bonneau, P. R.; Grand-Maître, C.; Greenwood, D. J.; Lagacé, L.; LaPlante, S. R.; Massariol, M.-J.; Ogilvie, W. W.; O'Meara, J. A.; Kawai, S. H. Evidence of a Conformational Change in the Human Cytomegalovirus Protease upon Binding of Peptidyl-Activated Carbonyl Inhibitors. Biochemistry 1997, 36, 12644-12652.
50. de Oliveira, C. A. F.; Guimaràes, C. R. W.; Barreiro, G.; Alencastro, R. B. Investigation of the Induced-Fit Mechanism and Catalytic Activity of the Human Cytomegalovirus Protease Homodimer via Molecular Dynamics Simulations. Proteins 2003, 52, 483-491.
51. Batra, R.; Khayat, R.; Tong, L. Molecular Mechanism for Dimerization to Regulate the Catalytic Activity of Human Cytomegalovirus Protease. Nat. Struct. Biol. 2001, 8, 810-817.
52. Darke, P. L.; Cole, J. L.; Waxman, L.; Hall, D. L.; Sardana, M. K.; Kuo, L. C. Active Human Cytomegalovirus Protease is a Dimer. J. Biol. Chem. 1996, 271, 7445-7449.
53. Case, D. A.; Perlman, D. A.; Caldwell, J. W.; Chetham, T. E., III; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. AMBER 7; University of California: San Francisco, CA, 1995.
54. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A 2nd Generation Force-Field for the Simulation of Proteins, Nucleic-Acids, and Organic-Molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
55. Hunenberger, P. H.; Mark, A. E.; Gunsteren, W. F. Fluctuation and Cross-Correlation Analysis of Protein Motions Observed in Nanosecond Molecular-Dynamics Simulations. J. Mol. Biol. 1995, 252, 492-503.
56. Estabrook, R. A.; Luo, J.; Purdy, M. M.; Sharma, V.; Weakliem, P.; Bruice, T. C.; Reich, N. O. Statistical Coevolution Analysis and Molecular Dynamics: Identification of Amino Acid Pairs Essential for Catalysis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 994-999.
57. Mazumder-Shivakumar, D.; Bruice, T. C. Computational Study of IAG-Nucleoside Hydrolase: Determination of the Preferred Ground State Conformation and the Role of Active Site Residues. Biochemistry 2005, 44, 7805-7817.
58. Zoete, V.; Meuwly, M.; Karplus, M. A Comparison of the Dynamic Behavior of Monomeric and Dimeric Insulin Shows Structural Rearrangements in the Active Monomer. J. Mol. Biol. 2004, 342, 913-929.
59. Harte, W. E., Jr.; Swaminathan, S.; Beveridge, D. Molecular Dynamics of HIV-I Protease. Proteins 1992, 13, 175-194.
60. Ichiye, T.; Karplus, M. Collective Motions in Proteins: A Covariance Analysis of Atomic Fluctuations in Molecular Dynamics and Normal Mode Simulations. Proteins 1991, 11, 205-217.
61. Luo, J.; Bruice, T. C. Ten-Nanosecond Molecular Dynamics Simulation of the Motions of the Horse Liver Alcohol Dehydrogenase. PhCH2O- complex. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 16597-16600.
62. Hammes-Schiffer, S.; Benkovic, S. J. Relating Protein Motion to Catalysis. Annu. Rev. Biochem. 2006, 75, 519-541.
63. Liang, Po-H.; Brun, K. A.; Feild, J. A.; O'Donnell, K.; Doyle, M. L.; Green, S. M.; Baker, A. E.; Blackburn, M. N.; Abdel-Meguid, S. S. Site-Directed Mutagenesis Probing the Catalytic Role of Arginines 165 and 166 of Human Cytomegalovirus Protease. Biochemistry 1998, 37, 5923-5929.